EUCTR2010-022782-99-DE进行中（未招募）不适用
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA (CIU) WHO REMAIN SYMPTOMATIC DESPITE ANTIHISTAMINE TREATMENT (H1) - ASTERIA I
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 302
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet the following criteria for study entry:
- •1. Aged 12-75 years (age limits may vary dependent upon regional restrictions).
- •2. Diagnosis of CIU refractory to H1 antihistamines at the time of randomization,
- •as defined by all of the following:
- •The presence of itch and hives for = 8 consecutive weeks at any time prior
- •to enrollment despite current use of H1 antihistamine treatment during this
- •time period UAS7 score (range 0-42) = 16 and itch component of UAS7 (range 0-21)
- •= 8 during 7 days prior to randomization (Week 0) In-clinic UAS = 4 on at least one of the screening visit days (Day -14, Day - 7 or Day 1) Patients must have been on an approved dose of an H1 antihistamine for CIU for at least the 3 consecutive days immediately prior to the Day -14 screening visit and must document current use on the day of the initial screening visit. CIU diagnosis for = 6 months.
- •3. Willing to give written informed consent, adhere to the visit schedules and meet
- •study requirements.For those patients below the legal age of consent, the child must be willingto give written informed assent and the parent(s)/guardian(s) must be willing to give written informed consent. For patients below the legal age of consent, both child and parent must be able to adhere to dose and visit schedules and meet study requirements.
- •4. Willing and able to complete a daily symptom eDiary for the duration of the
- •5. Patients must not have any missing eDiary entries in the 7 days prior to
- •randomization.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 65
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •Patients who meet any of the following criteria will be excluded from study entry:
- •1. Treatment with an investigational agent within 30 days of Day -14.
- •2. Weight less than 20 kg (44 lbs).
- •3. Clearly defined underlying etiology for chronic urticarias other than CIU (main
- •manifestation being physical urticaria). This includes the following urticarias:
- •Acute, solar, cholinergic, heat, cold, aquagenic, delayed pressure or contact
- •As well as the following diseases as these diseases may have symptoms
- •of urticaria or angioedema Urticarial vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary or acquired angioedema, lymphoma, leukemia,
- •or generalized cancer.
- •4. Evidence of parasitic infection defined as having the following three items:
- •Risk factors for parasitic disease (living in an endemic area, chronic GI symptoms, travel within the last 6 months to an endemic area and/or chronic immunosuppression)
- •An absolute eosinophil count more than twice the upper limit of normal
- •Evidence of parasitic colonization or infection on stool evaluation for ova and
- •parasites. Note that stool ova and parasite evaluation will only be conducted
- •in patients with both risk factors and an eosinophil count more than twice the
- •upper limit of normal.
- •5. Atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus
- •or other skin disease associated with itch.
- •6. Previous treatment with omalizumab within a year prior to Day -14.
- •7. Routine (daily or every other day during 5 or more consecutive days) doses of
- •the following medications within 30 days prior to Day -14: systemic or cutaneous (topical) corticosteroids (prescription or over the counter), hydroxychloroquine, methotrexate, cyclosporine, or cyclophosphamide.
- •8. IV immunoglobulin G (IVIG), or plasmapheresis within 30 days prior to Day -14.
- •9. Regular (daily/every other day) doxepin (oral) use within 14 days prior to
- •10. Any H2 antihistamine use within 7 days prior to Day -14.
- •11. Any LTRA (montelukast or zafirlukast) within 7 days prior to Day -14.
- •12. Any H1 antihistamines at greater than approved doses within 3 days prior to
- •13. Patients with current malignancy, history of malignancy, or currently under
- •work-up for suspected malignancy except non-melanoma skin cancer that has
- •been treated or excised and is considered resolved.
- •14 .Hypersensitivity to omalizumab or any component of the formulation.
- •15. History of anaphylactic shock.
- •16. Presence of clinically significant cardiovascular, neurological, psychiatric,
- •metabolic or other pathological conditions that could interfere with the
- •interpretation of the study results and or compromise the safety of the patients.
- •17. Medical examination or laboratory findings that suggest the possibility of
- •decompensation of co-existing conditions for the duration of the study.
- •Any items that are cause for uncertainty must be reviewed with the Medical Monitor.
- •18. Inability to comply with study and follow-up procedures.
- •19. Evidence of current drug or alcohol abuse.
- •20. Nursing women or women of childbearing potential, defined as all women
- •physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of natural (sp
研究者
相似试验
进行中（未招募）
1 期
A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy after Definitive Local Therapy in Patients with High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neckocally advanced squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 21.0Level: PTClassification code 10041823Term: Squamous cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003302-40-BEF. Hoffman-La Roche Ltd.406
进行中（未招募）
不适用
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY STUDY OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA (CIU) WHO REMAIN SYMPTOMATIC DESPITE TREATMENT WITH H1 ANTIHISTAMINES, H2 BLOCKERS, AND/OR LEUKOTRIENE RECEPTOR ANTAGONISTS - GLACIACHRONIC IDIOPATHIC URTICARIA (CIU)MedDRA version: 14.1Level: PTClassification code 10021247Term: Idiopathic urticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2010-022784-35-DEGenentech, Inc.321
已完成
3 期
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BALOXAVIR MARBOXIL IN COMBINATION WITH A NEURAMINIDASE INHIBITOR VERSUS A NEURAMINIDASE INHIBITOR ALONE IN HOSPITALIZED PATIENTS WITH SEVERE INFLUENZAInfluenzaNL-OMON48962Hoffmann-La Roche40
进行中（未招募）
1 期
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING, PLACEBO-CONTROLLED STUDY TO Evaluate the efficacy, RESPONSE DURATION and safety OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA (CIU) WHO REMAIN SYMPTOMATIC DESPITE ANTIHISTAMINE TREATMENT (H1) - ASTERIA IICHRONIC IDIOPATHIC URTICARIA (CIU)MedDRA version: 12.1Level: LLTClassification code 10021247Term: Idiopathic urticariaEUCTR2010-022785-27-FRGenentech, Inc.301
进行中（未招募）
1 期
A Study to Evaluate Efficacy and Safety of Gantenerumab in Patients with Early Alzheimer’s DiseaseAlzheimer’s Disease (AD)MedDRA version: 20.0Level: HLTClassification code 10001897Term: Alzheimer's disease (incl subtypes)System Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10074616Term: Prodromal Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2017-001365-24-SEF. Hoffmann-La Roche Ltd1,016